de Boer Daniel Anton purchased $238K of PRQR
de Boer Daniel Anton (Chief Executive Officer) purchased 150,000 shares of ProQR Therapeutics N.V. (PRQR) at $1.59 ($0.24M total) on 2026-07-07.
How this was made
The 30-second read
Why it matters
The CEO’s purchase is a sentiment input for traders, but it does not change guidance, trial outcomes, or financial forecasts in the text.
Market read
Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a major repricing.
What to watch
No 10b5-1 plan is cited, but the filing also lacks context on prior holdings, motivations, or whether other insiders are buying/selling.
Background
The article is an SEC Form 4 insider transaction disclosure for ProQR Therapeutics N.V.
Ticker impact
CEO de Boer bought 150,000 PRQR shares on 2026-07-07 at $1.5900, totaling $238,500, per SEC Form 4.
Near-term impact likely limited; any effect is more sentiment-driven than earnings or guidance-driven.
The filing is primary-source and time-stamped, but it provides no new company operating, clinical, or financial datapoints.
Market effects
No direct sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Insider open-market buys can be routine liquidity or diversification-related and may not signal near-term fundamentals.
Key entities
- issuerProQR Therapeutics N.V.
Subject of the Form 4 insider transaction; CEO de Boer reported an open-market purchase.
- insiderde Boer Daniel Anton
Chief Executive Officer and director who purchased 150,000 shares at $1.5900.